Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4910MR)

This product GTTS-WQ4910MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 608
UniProt ID Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4910MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8173MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HL161
GTTS-WQ15666MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ4639MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ144MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ11086MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MCS-110
GTTS-WQ9513MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA J2898A
GTTS-WQ3519MR IVTScrip™ mRNA-Anti-APP, BART(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BART
GTTS-WQ8537MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Hu5A8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW